Biosynth Intelligence Profile

biosynth.comLast reviewed: October 20, 2026Research coverage: 91%

Overall data confidence:Unknown

Identity confidence

High

8 of 10 identity fields independently documented

Corporate continuity

Continuity supported — domain registered 1996-04-17 for a company founded in 1966; the current site carries a >1M-product catalog and current content, and the legacy peptide-brand domains pepnet.com and vivitide.com redirect into biosynth.com following the 2022 merger/rebrand

Based on domain history and corporate record fields

Regulatory exposure

None identified

Derived from published risk flags

Evidence integrity

High

7 of 7 testing fields documented

Transaction transparency

High

4 of 5 commercial fields documented

Change activity

None tracked

0 change events tracked

Research Incomplete

Research coverage for this vendor is 91%. Our research on Biosynth remains incomplete — what we have verified so far is published below, and research is continuing.

Still to research:

Registration jurisdiction researched (state_of_registration)
Payment methods reviewed (accepted_payment_methods)
Public summary reviewed

Overview#

Biosynth is the Swiss-headquartered (Staad, founded 1966) life-science supply group owned by KKR, Ampersand Capital Partners and management, and one of the larger legitimate peptide manufacturers in this directory's scope: catalog and custom peptides, GMP peptide specialties and neoantigen work, with U.S. peptide operations in Gardner, MA and Louisville, KY inherited from vivitide — the 2019 merger of New England Peptide (1998) and Peptides International (1983) — acquired in March 2022. Documentation quality is high for a B2B supplier: lot-specific Certificates of Analysis are publicly hosted (a 2024-03-26 CoA for lot 10095/15 was inspected: UPLC purity vs specification, ESI-MS identity), QC panels are published in detail, and entity-specific, dated Terms & Conditions for Sale (including a restrictive but explicit U.S. returns regime) are public. All defined regulatory searches (FDA warning letters, recalls, import alerts, FTC, state AG, civil litigation, criminal/injunctive) returned No Record Found in the defined search. Open items are verification-depth issues, not red flags: the U.S. entity's state of registration and registered agent were not registry-verified in this pass (entity names rest on the group's own published U.S. terms naming Biosynth International Inc.), and accepted payment instruments are not published (B2B invoice terms only). No serious (High/Critical) findings. Caution for future researchers: Bio-Synthesis Inc. (biosyn.com, Texas) is a different company.

Company Identity#

Vendor Brand NameBiosynth

HighSource: Biosynth homepage

Primary Website Domainbiosynth.com

ModerateSource: Biosynth — official website (intake domain confirmation)

Legal Entity NameBiosynth AG (Swiss parent); U.S. sales entity named in the group's own published U.S. Terms & Conditions for Sale is Biosynth International Inc.

ModerateSource: Biosynth — Terms & Conditions for Sale, Biosynth International Inc. USA (2024-10-01)

State of RegistrationNot independently verified

UnknownSource: Biosynth — Terms & Conditions for Sale, Biosynth AG (HQ address Staad, Switzerland)

Entity StatusActive — group is trading and expanding (facility openings and acquisitions announced through 2023–2024; sites operating at intake)

ModerateSource: Business Wire (via novumpr) — Biosynth Suzhou facility opening, Oct 2024

Incorporation / Formation Date1966 — Biosynth founded in Staad, Switzerland by Hans Spitz

HighSource: C&EN — European firms Carbosynth and Biosynth merge (2019)

Named Principals / ManagersUrs Spitz — President (son of founder Hans Spitz). Ownership: KKR, Ampersand Capital Partners and management

ModerateSource: C&EN — European firms Carbosynth and Biosynth merge (2019)

Registered AgentNot independently verified

UnknownSource: Biosynth — Terms & Conditions for Sale, Biosynth International Inc. USA (no agent disclosed)

Operating AddressGroup HQ: Rietlistrasse 4, 9422 Staad, Switzerland. U.S. peptide sites listed by the company: Gardner, MA (peptide focus) and Louisville, KY (peptide focus & logistics hub)

HighSource: Biosynth — Terms & Conditions for Sale, Biosynth AG (Rietlistrasse 4, 9244/9422 Staad letterhead)

Address ConsistencyConsistent — the Staad HQ address appears identically in the company's Swiss terms documents and third-party directories, and the Gardner MA / Louisville KY U.S. locations are described consistently across the company site and the 2022 acquisition releases

ModerateSource: Biosynth — Terms & Conditions for Sale, Biosynth AG

Domain and Digital Identity#

Domain Registration Date1996-04-17

HighSource: Verisign RDAP — biosynth.com

Domain Ownership / Registrar Change HistoryCurrent registrar united-domains GmbH; RDAP record last changed 2026-09-27. Earlier registrar/ownership change history was not retrieved in this pass

LowSource: Verisign RDAP — biosynth.com

Website ContinuityContinuity supported — domain registered 1996-04-17 for a company founded in 1966; the current site carries a >1M-product catalog and current content, and the legacy peptide-brand domains pepnet.com and vivitide.com redirect into biosynth.com following the 2022 merger/rebrand

HighSource: Verisign RDAP — biosynth.com / pepnet.com

Contact Channel IntegrityPublished corporate channels: USA toll-free +1 (888) 681-2933, UK +44 (0)1635 578444, site contact forms and a published global site list — consistent with the group's directory and registry footprint

HighSource: Biosynth homepage — contact block and site list

Regulatory and Legal History#

FDA Warning Letter HistoryNo Record Found in the defined search

HighSource: Defined web search of FDA warning letters — no letter naming Biosynth entities

FDA Recall / Safety Action HistoryNo Record Found in the defined search

HighSource: Defined web search of FDA recalls — no recall naming Biosynth entities

FDA Import Alert / Detention ExposureNo Record Found in the defined search

ModerateSource: Defined web search of FDA import alerts — no alert naming Biosynth entities

FTC Enforcement HistoryNo Record Found in the defined search

HighSource: Defined web search of FTC enforcement — no action naming Biosynth

State Regulatory / Attorney General ActionsNo Record Found in the defined search

ModerateSource: Defined web search of state AG/regulatory actions — none naming Biosynth entities

Relevant Civil LitigationNo Record Found in the defined search

ModerateSource: Defined web search of litigation involving Biosynth peptide operations — none found

Criminal / Injunctive ProceedingsNo Record Found in the defined search

ModerateSource: Defined web search of criminal/injunctive proceedings — none naming Biosynth

Testing and COA Evidence#

Public COA AvailabilityYes — lot-specific Certificates of Analysis are publicly hosted on biosynth.com. Example inspected: Cat. No. CRB1000104 ('Click TP10'), Lot 10095/15, CoA dated 2024-03-26, reporting UPLC purity >95.0% against a min. 95.0% specification and ESI-MS identity

HighSource: Biosynth — Certificate of Analysis, CRB1000104 Lot 10095/15 (2024-03-26)

Batch / Lot SpecificityLot-specific — CoAs carry catalog number and lot number with lot-matched results (example: Lot 10095/15, purity result vs specification, issue date)

HighSource: Biosynth — Certificate of Analysis, CRB1000104 Lot 10095/15

Independent Laboratory IdentityNo independent third-party laboratory is named for catalog peptide CoAs; testing is performed by Biosynth's in-house QC laboratories at ISO 9001 / GMP group sites

ModerateSource: Biosynth — GMP Peptide Specialities (analytical techniques)

COA Verification StatusCoAs are vendor-issued and publicly downloadable from the vendor's own site; no independent third-party verification portal was found. Peptide QC is documented as performed in-house (ESI-MS identity, UPLC purity)

ModerateSource: Biosynth — Certificate of Analysis, CRB1000104 Lot 10095/15

Test RecencyThe most recent CoA independently inspected in this pass is dated 2024-03-26; QC method pages are current. No dated third-party (independent) test results were found

ModerateSource: Biosynth — Certificate of Analysis, CRB1000104 Lot 10095/15 (2024-03-26)

Testing CoverageDocumented peptide QC panel — GMP lines: identity (ESI-MS), purity/impurities (UPLC/UV), amino-acid sequence (HR-MS/MS), net peptide content, enantiomeric purity, counterion, residual solvents, water content, endotoxin, bioburden. Research grade (per CoA): UPLC purity and ESI-MS identity

HighSource: Biosynth — GMP Peptide Specialities (analytical techniques list)

Evidence ConsistencyConsistent — founding (1966), HQ (Staad), U.S. locations, the acquisition chain (Carbosynth 2019; vivitide 2022; Pepceuticals and VIO Chemicals 2023) and ownership (KKR/Ampersand/management) agree across the company site, ACS trade press and Business Wire releases. One standing caution: the similarly named Bio-Synthesis Inc. (Texas) is unrelated and must not be conflated

ModerateSource: C&EN — Carbosynth/Biosynth merger; Business Wire releases via novumpr

Payment, Refund and Shipping#

Accepted Payment MethodsNot independently verified

UnknownSource: Biosynth — Terms & Conditions for Sale, Biosynth AG (§5 Payments: 30 days from invoice)

Refund / Return PolicyDocumented in the U.S. Terms & Conditions for Sale (Biosynth International Inc., §§21–22): products cannot be returned, and orders once accepted cannot be cancelled, without the seller's prior written consent and a return authorization number; unauthorized returns are refused; termination for convenience may incur a termination/restocking charge of 25–50% of the product price, and custom peptide orders are charged according to manufacturing progress before cancellation

HighSource: Biosynth — Terms & Conditions for Sale, Biosynth International Inc. USA, §§21–22

Shipping & Fulfillment RepresentationsPer the company's peptide FAQ: most peptides are shipped at room temperature in lyophilized state (stated stable for weeks); dry-ice shipment is arranged where required, at the customer's cost; light-sensitive products ship in dark bottles and oxidation-prone products under argon. U.S. distribution runs through the Gardner MA and Louisville KY sites

HighSource: Biosynth — Customer Support FAQs (peptide shipping conditions)

Terms / Policy StabilityEntity-specific Terms & Conditions for Sale are published per group company (AG Switzerland, International Inc. USA, GmbH Austria, s.r.o. Slovakia, Laboratories Ltd UK) as dated documents (current versions dated 2024-10-01) — versioned, stable B2B terms

ModerateSource: Biosynth — Terms & Conditions documents index (per-entity PDFs, 2024-10-01 versions)

Customer Complaint PatternNo Record Found in the defined search

ModerateSource: Defined web search for Biosynth complaints/reviews — no pattern found (name-collision results excluded)

Material Changes#

No material changes recorded.

Sources#

Biosynth — official website (intake domain confirmation)Tier 2 · Official/CommercialVendor Website

Retrieved: October 20, 2026